Cullinan Therapeutics (NASDAQ:CGEM) Shares Gap Up After Analyst Upgrade

Cullinan Therapeutics, Inc. (NASDAQ:CGEM) gapped up before the market opened on Thursday after Wedbush raised their price target on the stock from $39.00 to $42.00. The stock had previously closed at $19.60, but opened at $20.72. Wedbush currently has an outperform rating on the stock. Cullinan Therapeutics shares last traded at $20.4230, with a volume of 243,271 shares trading hands.

Other equities research analysts have also issued research reports about the company. BTIG Research lifted their price objective on Cullinan Therapeutics from $38.00 to $39.00 and gave the stock a “buy” rating in a report on Wednesday, July 29th. Wall Street Zen downgraded shares of Cullinan Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, August 1st. Weiss Ratings reiterated a “sell (d-)” rating on shares of Cullinan Therapeutics in a research report on Wednesday, July 8th. Finally, HC Wainwright reiterated a “buy” rating and set a $30.00 target price on shares of Cullinan Therapeutics in a research report on Monday, June 8th. Six investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Cullinan Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $32.86.

Insider Buying and Selling at Cullinan Therapeutics

In other news, insider Jennifer Michaelson sold 8,000 shares of Cullinan Therapeutics stock in a transaction on Monday, July 6th. The stock was sold at an average price of $17.82, for a total value of $142,560.00. Following the completion of the transaction, the insider directly owned 162,844 shares in the company, valued at approximately $2,901,880.08. The trade was a 4.68% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 8.60% of the company’s stock.

Key Stories Impacting Cullinan Therapeutics

Here are the key news stories impacting Cullinan Therapeutics this week:

• Positive Sentiment: Analysts maintain a favorable view of Cullinan Therapeutics. The company received an average “Moderate Buy” rating, while HC Wainwright reiterated its “Buy” rating and $30 price target—well above the roughly $19.60 reference price. Cullinan Therapeutics Receives Average Rating of Moderate Buy from Analysts
• Positive Sentiment: HC Wainwright’s 2027 quarterly forecasts call for progressively smaller losses, including estimated EPS of $(0.77) in the first quarter and $(0.82) in the fourth quarter, suggesting expectations for gradual improvement over time. Cullinan Therapeutics analyst estimates
• Neutral Sentiment: Reported short interest was zero shares as of August 11, unchanged from the prior report. With a zero days-to-cover ratio, the data provides no evidence of meaningful short-selling pressure or a potential short squeeze.
• Negative Sentiment: HC Wainwright lowered its 2026 EPS forecast to a $(3.53) loss from $(3.42), and cut its third-quarter 2026 estimate to $(0.90) from $(0.87) and fourth-quarter estimate to $(0.93) from $(0.90). The revisions reinforce that Cullinan remains loss-making and may require continued spending or financing while advancing its pipeline.

Institutional Investors Weigh In On Cullinan Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of CGEM. Connor Clark & Lunn Investment Management Ltd. bought a new position in shares of Cullinan Therapeutics in the second quarter valued at approximately $5,326,000. Quantbot Technologies LP purchased a new position in Cullinan Therapeutics during the second quarter valued at approximately $53,000. Ieq Capital LLC bought a new stake in Cullinan Therapeutics during the 2nd quarter worth approximately $614,000. Allworth Financial LP bought a new stake in Cullinan Therapeutics during the 2nd quarter worth approximately $53,000. Finally, Blue Owl Capital Holdings LP purchased a new stake in Cullinan Therapeutics in the 2nd quarter worth approximately $28,039,000. 86.31% of the stock is owned by hedge funds and other institutional investors.

Cullinan Therapeutics Trading Up 2.2%

The company’s fifty day simple moving average is $16.81 and its 200 day simple moving average is $14.99. The stock has a market capitalization of $1.29 billion, a P/E ratio of -6.51 and a beta of 0.01.

Cullinan Therapeutics (NASDAQ:CGEM) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.81) EPS for the quarter, missing analysts’ consensus estimates of ($0.80) by ($0.01). Equities research analysts predict that Cullinan Therapeutics, Inc. will post -3.03 earnings per share for the current year.

Cullinan Therapeutics Company Profile

Cullinan Therapeutics, Inc, a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer.